Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx

5

X.g Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

3
Last update : 15/05/2018
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Atezolizumab
2
Avelumab
1
CTLA4 blocking immunotherapy
3
Camrelizumab
1
Ipilimumab
4
Lambrolizumab
4
Nivolumab
5
PD-1/PD-L1-inhibitors or blocking agents/drugs
5
Pedelizumab
1
Pembrolizumab
5
Tislelizumab
1
Tremelimumab
1
Vaccination - Immunization
2
Vaccines
3
Zimberelimab
1

Publications

Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor-monoclonal antibodies and desensitization.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2021 Jun;126;623-629 2021 Jun
Pneumotoxicity associated with immune checkpoint inhibitor therapies.
Current opinion in pulmonary medicine 2017 Jul;23;305-316 2017 Jul

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies